This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12). Secondary endpoints include effects on liver fat content and other liver and lipid markers, as well as effects on safety and tolerability, and pharmacokinetic (PK) measurements.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
59
Radiant Research, Inc.
Chandler, Arizona, United States
SC Clinical Research
Garden Grove, California, United States
Change in LDL-C in patients receiving VK2809 compared to placebo
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ACTCA
Los Angeles, California, United States
Catalina Research Institute
Montclair, California, United States
North America Research, Inc
Pomona, California, United States
Orange County Research Center
Tustin, California, United States
Research Institute of South Florida
Miami, Florida, United States
Research Institute of South Florida
Miami, Florida, United States
Avant Research Associates, LLC
Crowley, Louisiana, United States
HCI- MetroMedic Walk-in
New Bedford, Massachusetts, United States
...and 9 more locations